drugset
drugset / Trial / NCT00627120

Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects

NCT00627120 ↗

Phase 1 Completed 48 enrolled VGX Pharmaceuticals, LLC GeneOne Life Science, Inc. · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of a single dose of VGX-1027 in the range of 1-800mg.

Timeline

Start
2008-02
Primary completion
2008-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject VGX-1027 Small molecule 1 mg —
Subject VGX-1027 Small molecule 10 mg —
Subject VGX-1027 Small molecule 100 mg —
Subject VGX-1027 Small molecule 200 mg —
Subject VGX-1027 Small molecule 400 mg —
Subject VGX-1027 Small molecule 800 mg —

Indications

No indication recorded.